L. Tarriff Scott's most recent trade in Eagle Pharmaceuticals Inc was a trade of 2,119 Common Stock done at an average price of $6.3 . Disclosure was reported to the exchange on Feb. 28, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.27 per share. | 28 Feb 2024 | 2,119 | 460,621 (3%) | 0% | 6.3 | 13,286 | Common Stock |
| Eagle Pharmaceuticals Inc | Tarriff L. Scott | Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 12,950 | 465,894 (3%) | 0% | - | Common Stock | |
| Eagle Pharmaceuticals Inc | L. Tarriff Scott | Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.44 per share. | 27 Feb 2024 | 3,154 | 462,740 (3%) | 0% | 6.4 | 20,312 | Common Stock |
| Eagle Pharmaceuticals Inc | Scott Tarriff L. | Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.13 per share. | 05 Jan 2024 | 4,322 | 541,125 (3%) | 0% | 5.1 | 22,172 | Common Stock |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 19.98 per share. | 16 May 2023 | 15,000 | 587,311 (4%) | 0% | 20.0 | 299,700 | Common Stock |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 20.71 per share. | 11 May 2023 | 15,000 | 1,624,934 (11%) | 0% | 20.7 | 310,650 | Common Stock |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 21.06 per share. | 11 May 2023 | 14,800 | 1,595,134 (11%) | 0% | 21.1 | 311,688 | Common Stock |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 20.42 per share. | 11 May 2023 | 11,869 | 1,609,934 (11%) | 0% | 20.4 | 242,365 | Common Stock |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 19.69 per share. | 11 May 2023 | 3,131 | 1,621,803 (11%) | 0% | 19.7 | 61,649 | Common Stock |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 21.52 per share. | 11 May 2023 | 200 | 1,594,934 (11%) | 0% | 21.5 | 4,304 | Common Stock |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 70,900 | 1,639,934 (11%) | 0% | 0 | Common Stock | |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.00 per share. | 28 Feb 2023 | 3,113 | 1,569,034 (11%) | 0% | 28 | 87,164 | Common Stock |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.64 per share. | 23 Jan 2023 | 3,732 | 1,572,147 (11%) | 0% | 33.6 | 125,544 | Common Stock |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.26 per share. | 05 Jan 2023 | 3,827 | 1,575,879 (11%) | 0% | 29.3 | 111,978 | Common Stock |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 34,800 | 1,579,706 (11%) | 0% | 0 | Common Stock | |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.78 per share. | 01 Apr 2021 | 31,201 | 1,561,184 (11%) | 0% | 8.8 | 273,945 | Common Stock |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2021 | 31,201 | 0 | - | - | Employee Stock Option (right to buy) | |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Apr 2021 | 16,340 | 1,529,983 (11%) | 0% | 0 | Common Stock | |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.87 per share. | 01 Apr 2021 | 16,278 | 1,544,906 (11%) | 0% | 41.9 | 681,560 | Common Stock |
| Eagle Pharmaceuticals Inc | Scott L. Tarriff | Director, CEO, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.70 per share. | 23 Jan 2021 | 4,631 | 1,546,323 (11%) | 0% | 47.7 | 220,899 | Common Stock |